I graduated with a Bachelor’s degree in Biological Sciences in 2021 and a Master’s degree in Health Biology in 2024 from the University of Siena. 
My academic and professional journey has focused on the development of therapeutic proteins, particularly monoclonal antibodies. During my MSc thesis at the Toscana Life Sciences Foundation in Siena and a research project abroad as part of my Erasmus at the Technical University of Denmark (DTU), I worked on the discovery of therapeutic antibodies using advanced technologies, including single B cell screening and phage display. 
Since September 2024, I have been working at Philogen S.p.A. in Siena, where I am involved in the development and optimization of industrial processes for biopharmaceutical production. These experiences have provided me with a comprehensive view of therapeutic proteins life cycle, from early discovery stages to industrial production, and broadened my awareness of innovations and applications in this field.
My research
In recent years, biotherapeutics have become essential for the treatment of many diseases, including cancer, offering targeted-therapies and more efficient approaches than conventional drugs. 
My PhD project, carried out in partnership with Philogen S.p.A in Siena, focuses on the development and optimization of industrial biotechnological processes for the production of recombinant therapeutic proteins, particularly monoclonal antibodies and their derivatives.
Within this context, designing a robust, efficient and scalable process for industrial production is essential to ensure product quality, safety, clinical efficacy and compliance with GMP standards. Achieving these goals requires identifying optimal key parameters in both upstream processes, which include cell expansion and protein production, and downstream processes, related to protein purification and formulation, in order to maximize yield, purity and product stability, while reducing development time and costs.